Hercules Capital Inc Stock Price, News & Analysis

Hercules Capital, Inc. (NYSE: HTGC) is actively supporting its portfolio amid the FDIC's decision to place Silicon Valley Bank under receivership. With over $16 billion committed to venture-backed companies, Hercules has earmarked $50 million for short-term financing to assist affected businesses. The company ended 2022 with assets under management exceeding $3.6 billion, showing a 29.3% year-over-year increase, alongside strong liquidity of $606 million. Hercules expects record funding performance in Q1 2023 and has maintained a diversified portfolio, with no direct exposure to SVB, ensuring minimal operational impact.

Hercules Capital, Inc. (NYSE: HTGC) announced participation in the RBC Capital Markets 2023 Financial Institutions Conference on March 7, 2023, in New York, NY. The company is a leading specialty finance provider focused on senior secured loans to high-growth, venture-backed companies across various sectors, including technology and life sciences. Since its inception in December 2003, Hercules has committed over $16 billion to more than 600 companies. Additionally, Hercules Adviser LLC manages investments for external parties. The company also has a retail bond issuance of 6.25% Notes due 2033 (NYSE: HCXY).

Hercules Capital (NYSE: HTGC) announced its financial results for Q4 and full-year 2022, highlighting record total gross debt and equity commitments of $3.12 billion and net investment income (NII) of $188.1 million, up 25.4% from the previous year. The total investment income for Q4 reached $100.2 million, increasing 38.3%. The company enhanced its cash distribution to $0.39 per share and announced a supplementary cash distribution of $0.32 for 2023. Additionally, it reported an increase in assets under management to over $3.6 billion, a 29.3% increase year-over-year.

Hercules Capital has announced a new supplemental cash distribution of $0.08 per share for the fourth quarter of 2022, in addition to the regular distribution of $0.39 per share. This distribution, totaling $0.32 per share over four quarters, will be paid from undistributed taxable income as of December 31, 2022. The record date for this payment is March 2, 2023, with payments made on March 9, 2023. Approximately 89.65% of the distributions will qualify as Qualified Interest Income exempt from U.S. withholding tax for foreign shareholders.

Hercules Capital, Inc. (NYSE: HTGC) has declared a fourth quarter 2022 cash distribution of $0.39 per share, with a record date of March 2, 2023 and a payment date of March 9, 2023. The company follows a variable distribution policy aiming to distribute approximately 90% to 100% of its taxable income each year. For the fourth quarter, 100% of distributions came from current and accumulated earnings. Notably, 89.65% of the declared distributions were categorized as Qualified Interest Income, potentially exempt from U.S. tax for foreign investors. Hercules has committed over $16 billion to more than 600 companies since its inception in December 2003.

Provention Bio, Inc. (Nasdaq: PRVB) has announced the closing of a $40 million second tranche under a $125 million term loan facility with Hercules Capital (NYSE: HTGC). This funding aims to support the commercial launch of TZIELD^®, a treatment for Stage 2 type 1 diabetes. CEO Ashleigh Palmer highlighted the positive reception of TZIELD^® from patients and prescribers, noting favorable coverage policies from major payers. The loan facility will be drawn in multiple tranches, with further funding contingent upon milestone achievements. The revised loan terms will lower the interest rate, enhancing financial flexibility.

Hercules Capital, Inc. (NYSE: HTGC) has announced its conference call for fourth quarter and full-year 2022 financial results, scheduled for February 16, 2023, at 2:00 p.m. PT. The company, a leader in providing specialty financing to innovative growth companies, will release its financial results after market close that day. Hercules has committed over $16 billion to more than 600 companies since its inception in December 2003, focusing primarily on technology and life sciences sectors. Investors can access the call via registration, with a live webcast also available on its investor relations website.

Hercules Capital (NYSE: HTGC) announced its participation in the KBW BDC Midtown event on December 14, 2022, in New York, NY. The company, a leading specialty finance provider, focuses on senior secured venture growth loans for high-growth, venture capital-backed firms across technology, life sciences, and renewable sectors. Since December 2003, Hercules has committed over $16 billion to more than 600 companies, positioning itself as a crucial lender for entrepreneurs. Additionally, Hercules has a retail bond issuance (NYSE: HCXY).

On November 16, 2022, Silicon Valley Bank and Hercules Capital announced a $300 million credit facility for Oak Street Health (NYSE: OSH). This financing aims to support Oak Street's operational and strategic initiatives over several years. The partnership reflects strong relationships built over the years. Oak Street Health focuses on value-based primary care for Medicare-eligible patients, particularly those in underserved communities. The collaboration underlines both banks' commitment to healthcare innovation and Oak Street's growth.